Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Goodwill: 2018-2025

Historic Goodwill for Akebia Therapeutics (AKBA) over the last 7 years, with Sep 2025 value amounting to $59.0 million.

  • Akebia Therapeutics' Goodwill changed negligibly% to $59.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $59.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • Akebia Therapeutics' Goodwill amounted to $59.0 million in Q3 2025, which was down 0.00% from $59.0 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Goodwill peaked at $59.0 million during Q4 2021, and registered a low of $55.1 million during Q1 2021.
  • Over the past 3 years, Akebia Therapeutics' median Goodwill value was $59.0 million (recorded in 2025), while the average stood at $59.0 million.
  • Data for Akebia Therapeutics' Goodwill shows a peak YoY increased of 7.16% (in 2021) over the last 5 years.
  • Over the past 5 years, Akebia Therapeutics' Goodwill (Quarterly) stood at $59.0 million in 2021, then remained steady at $59.0 million in 2022, then remained steady at $59.0 million in 2023, then remained steady at $59.0 million in 2024, then remained steady at $59.0 million in 2025.
  • Its Goodwill stands at $59.0 million for Q3 2025, versus $59.0 million for Q2 2025 and $59.0 million for Q1 2025.